Bionical Emas Revenue and Competitors

Hitchin, UK

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Bionical Emas's estimated annual revenue is currently $146.1M per year.(i)
  • Bionical Emas's estimated revenue per employee is $201,000

Employee Data

  • Bionical Emas has 727 Employees.(i)

Bionical Emas's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
SVP, Quality Assurance at Bionical EmasReveal Email/Phone
3
EVP, CTSReveal Email/Phone
4
VP Clinical Trial Supply - USReveal Email/Phone
5
Head Patient AccessReveal Email/Phone
6
EVP Information TechnologyReveal Email/Phone
7
Head Project ManagementReveal Email/Phone
8
EVP, Clinical DevelopmentReveal Email/Phone
9
Head Account ManagementReveal Email/Phone
10
Head Project Management, Early Access ProgramsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$58.9M2936%N/AN/A
#2
$21.1M1055%N/AN/A
#3
$113.4M5641%N/AN/A
#4
$20.9M104-5%N/AN/A
#5
$37M1849%N/AN/A
#6
$45.4M226-24%N/AN/A
#7
$16.1MN/AN/AN/A
#8
$69.7M3470%N/AN/A
#9
$8M403%N/AN/A
#10
$25.5M12728%N/AN/A
Add Company

What Is Bionical Emas?

Bionical Emas is the first and only CRO that combines Clinical Development, Early Access Programs and Clinical Trial Supply. We build close partnerships with our clients, so we can provide you with a unique, integrated service shaped to fit your needs.\n\nOur unique structure allows us to deliver combined projects more seamlessly, bringing your drugs to market more quickly and helping you to provide earlier access to medicine for patients.

keywords:N/A

N/A

Total Funding

727

Number of Employees

$146.1M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

Bionical Emas News

2022-03-22 - Ian Fraser appointed as EVP Clinical Development

Bionical Emas is a global Contract Research Organisation (CRO) business which combines clinical development, early access program and clinical...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$327.2M80659%N/A